Who Generates More Revenue? GSK plc or Teva Pharmaceutical Industries Limited

GSK leads revenue race against Teva over a decade.

__timestampGSK plcTeva Pharmaceutical Industries Limited
Wednesday, January 1, 20142300600000020272000000
Thursday, January 1, 20152392300000019652000000
Friday, January 1, 20162788900000021903000000
Sunday, January 1, 20173018600000022385000000
Monday, January 1, 20183082100000018854000000
Tuesday, January 1, 20193375400000016887000000
Wednesday, January 1, 20203409900000016658000000
Friday, January 1, 20213411400000015878000000
Saturday, January 1, 20222932400000014925000000
Sunday, January 1, 20233032800000015846000000
Monday, January 1, 202416544000000
Loading chart...

Cracking the code

Revenue Battle: GSK vs. Teva

In the competitive landscape of the pharmaceutical industry, revenue generation is a key indicator of a company's market strength. Over the past decade, GSK plc has consistently outperformed Teva Pharmaceutical Industries Limited in terms of revenue. From 2014 to 2023, GSK's revenue grew by approximately 32%, peaking in 2021 with a 48% increase from its 2014 figures. In contrast, Teva's revenue saw a decline of about 22% over the same period, with its highest revenue recorded in 2017. This trend highlights GSK's robust market strategies and product portfolio, which have enabled it to maintain a competitive edge. Meanwhile, Teva faces challenges in sustaining its revenue growth, reflecting the broader pressures in the generic drug market. As the pharmaceutical landscape evolves, these revenue trends offer insights into the strategic directions and market positions of these industry giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025